Avsola is designed to treat rheumatoid arthritis, Crohn’s disease, plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
Avsola is now the fourth FDA-approved biosimilar for Remicade, following Pfizer’s Ixifi, Merck’s Renflexis, and Celltrion’s Inflectra.
Amgen, which announced the approval Dec. 6, did not say when Avsola would be available for sale.
Read the full news release here.
More articles on pharmacy:
UnitedHealth to acquire struggling specialty pharmacy
Pharmaceutical layoffs up nearly 6% from last year
Larger chunk of hospital drug spending going toward cancer treatments, study finds
